Literature DB >> 434244

Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine.

W O Shekim, H Dekirmenjian, J L Chapel.   

Abstract

The authors studied the excretion of 3-methoxy-4-hydroxyphenlyglycol (MHPG) in 15 hyperactive boys and 13 controls. They further examined soft neurologic signs and clinical drug response to d-amphetamine administration for two weeks in the hyperactive boys. MHPG excretion was significantly lower in the hyperactive boys than in the controls. d-Amphetamine decreased MHPG excretion significantly in the drug responders only. Pretreatment MHPG excretion did not predict clinical drug response. The responders had more soft neurologic signs than the nonresponders. Furthermore, soft neurologic signs were not related to pretreatment MHPG levels.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434244     DOI: 10.1176/ajp.136.5.667

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  4 in total

Review 1.  Attention deficits and hyperactivity.

Authors:  P B Rosenberger
Journal:  Indian J Pediatr       Date:  1990 May-Jun       Impact factor: 1.967

2.  Reliability of neurological soft signs in children: reevaluation of the PANESS.

Authors:  E W Holden; K J Tarnowski; R J Prinz
Journal:  J Abnorm Child Psychol       Date:  1982-06

3.  Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.

Authors:  Rozita Davari-Ashtiani; Mahin Eslami Shahrbabaki; Katayoon Razjouyan; Homayoun Amini; Homa Mazhabdar
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

4.  Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response.

Authors:  Weiwei Jiang; Guanghui Jin; Fangfang Cai; Xiao Chen; Nini Cao; Xiangyu Zhang; Jia Liu; Fei Chen; Feng Wang; Wei Dong; Hongqin Zhuang; Zi-Chun Hua
Journal:  Exp Mol Med       Date:  2019-02-21       Impact factor: 8.718

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.